



(51) International Patent Classification:

A61K 31/53 (2006.01) A61P 35/00 (2006.01)
A61K 31/675 (2006.01) C07D 487/04 (2006.01)

(21) International Application Number:

PCT/US2024/039552

(22) International Filing Date:

25 July 2024 (25.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/515,752 26 July 2023 (26.07.2023) US
63/554,735 16 February 2024 (16.02.2024) US

(71) Applicant: **KINNATE BIOPHARMA INC.** [US/US];
12830 El Camino Real, Suite 150, San Diego, CA 92130 (US).

(72) Inventors: **GRANDINETTI, Kathryn, B.**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US). **SURIBEN, Rowena**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US). **MILLER, Nichol, L.G.**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US). **POWELL, Benjamin**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US). **YUAN, Ding**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US). **WOMBLE, Scott**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US). **KOUDRIAKOVA, Tatiana**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US). **COX, Jason, M.**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US). **TYHONAS, John**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US).

KANIA, Robert, S.; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US). **WILLIAMS, Richard, Thomas**; 12830 El Camino Real, Suite 150, San Diego, CA 92130 (US).


(74) Agent: **HEADRICK, Kyle, M.** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF CANCER WITH A CDK INHIBITOR

Fig. 1A



(57) Abstract: Provided herein are compositions and methods for the treatment of cancer. Said compositions comprise a CDK2/4/6 inhibitor selected from the group consisting of (3S,4R)-4-[(5-fluoro-7-{5-[(2S)-1,1,1-trifluoropropan-2-yl]pyridin-2-yl}pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino]oxan-3-ol, (3S,4R)-4-[(5-fluoro-7-{5-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-yl}pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino]oxan-3-yl(2S)-2-amino-3-methylbutanoate, 5-chloro-7-(1-ethylcyclobutyl)-2-(((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazine-6-carbonitrile, (3S,4R)-4-{[5-chloro-6-cyano-7-(1-ethylcyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl]amino}oxan-3-yl(2S)-2-amino-3-methylbutanoate, (3S,4R)-4-{(7-{5-[1-(difluoromethyl)cyclopropyl]pyridin-2-yl}-5-fluoropyrrolo[2,1-f][1,2,4]triazin-2-yl)amino]oxan-3-ol, and (3S,4R)-4-{(7-{5-[1-(difluoromethyl)cyclopropyl]pyridin-2-yl}-5-fluoropyrrolo[2,1-f][1,2,4]triazin-2-yl)amino]oxan-3-yl(2S)-2-amino-3-methylbutanoate. Some embodiments comprise combination therapy featuring the CDK2/4/6 inhibitor with at least one additional oncology therapeutic agent. In some embodiments at least one additional oncology therapeutic agent comprises an endocrine therapy agent.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*